BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25408469)

  • 1. Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.
    Cozza EM; Cooper TK; Budgeon LR; Christensen ND; Schell TD
    Cancer Immunol Immunother; 2015 Mar; 64(3):325-36. PubMed ID: 25408469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors.
    Ryan CM; Staveley-O'Carroll K; Schell TD
    J Immunother; 2008; 31(9):906-20. PubMed ID: 18832997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors.
    Ward-Kavanagh LK; Kokolus KM; Cooper TK; Lukacher AE; Schell TD
    Cancer Immunol Immunother; 2018 Apr; 67(4):639-652. PubMed ID: 29332158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.
    Tatum AM; Mylin LM; Bender SJ; Fischer MA; Vigliotti BA; Tevethia MJ; Tevethia SS; Schell TD
    J Immunol; 2008 Sep; 181(6):4406-17. PubMed ID: 18768900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer.
    Ward-Kavanagh LK; Zhu J; Cooper TK; Schell TD
    Cancer Immunol Res; 2014 Aug; 2(8):777-88. PubMed ID: 24801834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model.
    Bourquin C; von der Borch P; Zoglmeier C; Anz D; Sandholzer N; Suhartha N; Wurzenberger C; Denzel A; Kammerer R; Zimmermann W; Endres S
    J Immunol; 2010 Aug; 185(4):2580-8. PubMed ID: 20644173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
    May KF; Chen L; Zheng P; Liu Y
    Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors.
    Plautz GE; Inoue M; Shu S
    Cell Immunol; 1996 Aug; 171(2):277-84. PubMed ID: 8806798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.
    Sandin LC; Orlova A; Gustafsson E; Ellmark P; Tolmachev V; Tötterman TH; Mangsbo SM
    Cancer Immunol Res; 2014 Jan; 2(1):80-90. PubMed ID: 24778163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
    Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
    Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
    Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
    Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
    Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ
    Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells.
    Wang LX; Shu S; Plautz GE
    Cancer Res; 2005 Oct; 65(20):9547-54. PubMed ID: 16230420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects.
    Welniak LA; Shorts L; Subleski J; Blazar BR; Wiltrout RH; Murphy WJ
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):534-9. PubMed ID: 15282531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors.
    Yorty JL; Tevethia SS; Schell TD
    Cancer Immunol Immunother; 2008 Jun; 57(6):883-95. PubMed ID: 18004562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma.
    Honeychurch J; Glennie MJ; Johnson PW; Illidge TM
    Blood; 2003 Aug; 102(4):1449-57. PubMed ID: 12714523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
    Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
    Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model.
    Díaz-Montero CM; El Naggar S; Al Khami A; El Naggar R; Montero AJ; Cole DJ; Salem ML
    Cancer Immunol Immunother; 2008 Apr; 57(4):563-72. PubMed ID: 17726606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD40 conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors.
    Otahal P; Knowles BB; Tevethia SS; Schell TD
    J Immunol; 2007 Nov; 179(10):6686-95. PubMed ID: 17982058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.